CLAIMS

1. Use of a vesicular formulation comprising one or more phospho or sulpholipids and one or more surfactants, in the absence of any non-lipid, non-surfactant pharmaceutically active agent, in the manufacture of a medicament for treating rosacea.

2. Use of a vesicular formulation comprising one or more phospho or sulpholipids and one or more surfactants, in the absence of any non-lipid, non-surfactant pharmaceutically active agent, in the manufacture of a medicament for use in the treatment of erythema associated with rosacea.

3. Use of a vesicular formulation comprising one or more phospho or sulpholipids and one or more surfactants, in the absence of any non-lipid, non-surfactant pharmaceutically active agent, in the manufacture of a medicament for the treatment of thread veins associated with rosacea.

4. Use according to any of Claims 1, 2 or 3, in which the formulation is a cream, lotion, ointment, gel, solution, spray, lacquer or film forming solution.

5. Use according to any preceding claim, in which the molar ratio of phospho or sulpholipid to surfactant is about 1:3 to about 30:1.

6. Use according to Claim 5, in which the molar ratio of phospho or sulpholipid to surfactant is about 2:1 to about 20:1.

7. Use according to any preceding claim, in which the formulation contains 0.2 to 10% by weight surfactant.

8. Use according to any preceding claim, in which the phospho or sulpholipid is phosphatidylcholine.

9. Use according to any preceding claim, in which the surfactant is selected from the group consisting of: polyoxyethylene sorbitans, polyhydroxyethylene stearates or polyhydroxethylene laurylethers.

10. Use according to any preceding claim, in which the surfactant is polysorbate 80 (Tween 80).

11. Use according to any preceding claim, in which the formulation comprises a total combination of phospho or sulpholipid and surfactant of between 6% and 14% by weight.

12. Use according to any preceding claim, in which the formulation comprises at least 20% by weight water.

CLAIMS

1. Use of a vesicular formulation comprising one or more phospholipids and one or more non-ionic surfactants, in the absence of any non-lipid, non-surfactant pharmaceutically active agent, in the manufacture of a medicament for treating rosacea.

2. Use of a vesicular formulation comprising one or more phospholipids and one or more non-ionic surfactants, in the absence of any non-lipid, non-surfactant pharmaceutically active agent, in the manufacture of a medicament for use in the treatment of erythema associated with rosacea.

3. Use of a vesicular formulation comprising one or more phospholipids and one or more non-ionic surfactants, in the absence of any non-lipid, non-surfactant pharmaceutically active agent, in the manufacture of a medicament for the treatment of thread veins associated with rosacea.

4. Use according to any of Claims 1, 2 or 3, in which the formulation is a cream, lotion, ointment, gel, solution, spray, lacquer or film forming solution.

5. Use according to any preceding claim, in which the molar ratio of phospholipid to surfactant is about 1:3 to about 30:1.

6. Use according to Claim 5, in which the molar ratio of phospholipid to surfactant is about 2:1 to about 20:1.

7. Use according to any preceding claim, in which the formulation contains 0.2 to 10% by weight surfactant.

8. Use according to any preceding claim, in which the phospholipid is phosphatidylcholine.

9. Use according to any preceding claim, in which the surfactant is selected from the group consisting of: polyoxyethylene sorbitans, polyhydroxyethylene stearates or polyhydroxethylene laurylethers.

10. Use according to any preceding claim, in which the surfactant is polysorbate 80 (Tween 80).

11. Use according to any preceding claim, in which the formulation comprises a total combination of phospholipid and surfactant of between 6% and 14% by weight.

12. Use according to any preceding claim, in which the formulation comprises at least 20% by weight water.

5